Gerhard Rogler
The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease
Vögelin M, Rogler G, Fried M, Sulz M, Zeitz J, Scharl S, Vavricka S, Frei P, Biedermann L, Scharl M. The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. PloS one 2016; 11:e0155218.
23.05.2016The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease
23.05.2016PloS one 2016; 11:e0155218
Vögelin Marius, Rogler Gerhard, Fried Michael, Sulz Michael, Zeitz Jonas, Scharl Sylvie, Vavricka Stephan R, Frei Pascal, Biedermann Luc, Scharl Michael
The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort
Spalinger M, Scharl M, Rogler G, Fried M, Vavricka S, Scharl S, Frei P, Sulz M, Rossel J, Zeitz J, Biedermann L, Voegelin M. The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort. Digestion 2016; 93:182-92.
27.02.2016The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort
27.02.2016Digestion 2016; 93:182-92
Spalinger Marianne R, Scharl Michael, Rogler Gerhard, Fried Michael, Vavricka Stephan R, Scharl Sylvie, Frei Pascal, Sulz Michael, Rossel Jean-Benoit, Zeitz Jonas, Biedermann Luc, Voegelin Marius
Monitoring colonoscopy withdrawal time significantly improves the adenoma detection rate and the performance of endoscopists
Vavricka S, Rogler G, Safroneeva E, Peter S, Beglinger C, Biedermann L, Manz M, Rechner R, Degen L, Sulz M, Schoepfer A. Monitoring colonoscopy withdrawal time significantly improves the adenoma detection rate and the performance of endoscopists. Endoscopy 2016
25.01.2016Monitoring colonoscopy withdrawal time significantly improves the adenoma detection rate and the performance of endoscopists
25.01.2016Endoscopy 2016
Vavricka Stephan R, Rogler Gerhard, Safroneeva Ekaterina, Peter Shajan, Beglinger Christoph, Biedermann Luc, Manz Michael, Rechner Roman, Degen Lukas, Sulz Michael, Schoepfer Alain M
Risk factors for complications in patients with ulcerative colitis
Manser C, Borovicka J, Seibold F, Vavricka S, Lakatos P, Fried M, Rogler G. Risk factors for complications in patients with ulcerative colitis. United European Gastroenterol J 2016; 4:281-7.
19.01.2016Risk factors for complications in patients with ulcerative colitis
19.01.2016United European Gastroenterol J 2016; 4:281-7
Manser Christine N, Borovicka Jan, Seibold Frank, Vavricka Stephan R, Lakatos Peter L, Fried Michael, Rogler Gerhard
Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey
Barthel C, Rogler G, Wiegand N, Sulz M, Fried M, Vavricka S, Frei P, Scharl M, Scharl S, Wiegand S, Biedermann L. Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey. Nutr J 2015; 14:78.
12.08.2015Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey
12.08.2015Nutr J 2015; 14:78
Barthel Christiane, Rogler Gerhard, Wiegand Nico, Sulz Michael, Fried Michael, Vavricka Stephan R, Frei Pascal, Scharl Michael, Scharl Sylvie, Wiegand Sandra, Biedermann Luc
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey
Vavricka S, Michetti P, Straumann A, Seibold F, Scharl M, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Bansky G, Schoepfer A, for the Swiss IBDnet. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis 2010
22.12.2010Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey
22.12.2010Inflamm Bowel Dis 2010
Vavricka Stephan R, Michetti Pierre, Straumann Alex, Seibold Frank, Scharl Michael, Sauter Bernhard, de Saussure Philippe, Rogler Gerhard, Manz Michael, Geyer Martin, Felley Christian, Binek Janek, Bansky Georg, Schoepfer Alain M, for the Swiss IBDnet
Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey
Schoepfer A, Straumann A, Seibold F, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Vavricka S, Michetti P. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey. Inflammatory bowel diseases 2009
10.12.2009Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey
10.12.2009Inflammatory bowel diseases 2009
Schoepfer Alain M, Straumann Alex, Seibold Frank, Sauter Bernhard, de Saussure Philippe, Rogler Gerhard, Manz Michael, Geyer Martin, Felley Christian, Binek Janek, Vavricka Stephan R, Michetti Pierre